- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06058091
RY_SW01 Cell Injection Therapy in Systemic Sclerosis
A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01 Cell Injection Therapy in Systemic Sclerosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This clinical trial is a multicenter Phase I/II clinical trial, which includes two stages: Phase I dose-escalation and Phase II dose-expansion. The Phase I dose-escalation stage adopts a single-arm trial design, aiming to explore the safety, tolerability, and preliminary efficacy of RY_SW01 cell injection in treating patients with systemic sclerosis. The Phase II dose-expansion stage adopts a randomized, double-blind controlled trial design, intending to explore the safety, efficacy, and changes in disease-related biomarkers of RY_SW01 cell injection in treating systemic sclerosis patients.
Based on the characteristics of this product and pre-clinical study data, as well as integrating the safety and efficacy data of similar types of drugs and clinical trials for the same or similar indications published domestically and internationally, the researchers and sponsors jointly selected the trial exploration doses as low dose 1.0×10^6 cells/kg and high dose 2.0×10^6 cells/kg.
The trial will enroll systemic sclerosis patients aged ≥18 and ≤65 years, who must meet all inclusion criteria and none of the exclusion criteria. Approximately 81-87 subjects are planned to be enrolled to undergo dose-escalation and dose-expansion trials with RY_SW01 cell injection. The dose-escalation stage plans to enroll 6-12 evaluable subjects, and the dose-expansion stage plans to enroll 75 subjects.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Ning Wei
- Phone Number: 15852926678
- Email: weining@rybiotech.cn
Study Contact Backup
- Name: Jing Wang
- Phone Number: 025-86162919
- Email: wangjing@rybiotech.cn
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Recruiting
- Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital, the Affiliated Drum Tower Hospital of Nanjing University Medical School
-
Contact:
- Sun Lingyun, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form.
- Aged between 18 and 65 years (inclusive), regardless of gender.
- Diagnosed with systemic sclerosis (SSc) based on the 2013 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria for SSc.
- Screened as diffuse cutaneous SSc patients with a disease duration of ≤5 years (disease onset defined as the time of the initial diagnosis of SSc).
- Previously treated with at least two of the following therapies: corticosteroids, immunosuppressants, biologic agents, and others, and have a skin score of 10≤mRSS≤30 points.
Exclusion Criteria:
- At screening, subjects with a forced vital capacity (FVC) predicted percentage <50%.
- Previously diagnosed with pulmonary arterial hypertension or, at rest, had a mean pulmonary arterial pressure >25mmHg measured by right heart catheterization or had a systolic pulmonary artery pressure >45mmHg measured by echocardiography at screening.
- Presence of clinical symptoms requiring hospitalization for one of the following conditions at screening, whether newly occurring or worsening of pre-existing symptoms within 6 months: myocardial infarction, stroke, renal crisis, severe uncontrolled hypertension (≥160/100mmHg); or within 3 months: unstable ischemic heart disease, uncontrolled arrhythmia, heart failure (New York Heart Association III/IV stage), left ventricular ejection fraction <50% as indicated by echocardiography, renal insufficiency, or hypertensive crisis as judged by the investigator.
- Concurrent autoimmune connective tissue diseases other than systemic sclerosis, with the exception of patients with secondary Sjögren's syndrome.
Presence of any of the following laboratory abnormalities at screening:
- Hematology abnormalities: Hemoglobin <100g/L; White blood cell count <3.0×109/L; Neutrophil absolute count <1.5×109/L; Platelet count <100×109/L.
- Hepatic function abnormalities: ALT or AST >3 times the upper limit of normal (ULN); Total bilirubin >3 times ULN.
- Renal function abnormalities: Estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2 or any clinically significant laboratory abnormalities that may affect the interpretation of study data or the subject's participation in the study as determined by the investigator.
- Positive testing for human immunodeficiency virus (HIV) antibody, active syphilis, active hepatitis C (positive HCV antibodies and positive HCV-RNA), HBsAg positive and HBV-DNA positive at screening; history of severe active bacterial, viral, fungal, parasitic, or other infections during the screening period.
- Receipt of live vaccines/attenuated vaccines within 2 months prior to enrollment.
- Occurrence of any of the following within 3 months prior to enrollment: a. Major trauma or major surgery (including joint surgery) or anticipated major surgery during the study, which the investigator believes would pose an unacceptable risk to the subject. b. Plasma exchange or extracorporeal photopheresis treatment. c. Participation in any other clinical trials.
- Prior treatment with stem cell-related drugs.
- History of any malignancy within the past 5 years prior to enrollment, except for adequately treated or excised basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical carcinoma.
- Intolerance or contraindication to the study treatment, including any of the following: a. Allergy to albumin contained in the investigational product excipient. b. Lack of suitable peripheral venous access.
History of smoking, alcohol abuse, or drug abuse within the past 12 months or during the screening period:
- Smoking defined as an average daily consumption of ≥5 cigarettes within the 3 months prior to screening.
- Alcohol abuse defined as consuming more than 14 units of alcohol per week (1 unit of alcohol = 350ml of beer, or 45ml of spirits, or 150ml of wine) within the 3 months prior to screening.
- Drug abuse defined as having a history of drug abuse.
- Plans for conception during the trial period until at least 1 year after cell infusion, unwillingness to use effective contraceptive measures with their partners, or plans for sperm or egg donation.
- Deemed unsuitable for participation in the study by the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Phase II-Placebo group
Receive the best basic treatment
|
Basic treatment for SSc
Other Names:
|
Experimental: Phase II-low-does group
Receive the best basic treatment and a million cells per kilogram of body weight
|
Basic treatment for SSc
Other Names:
Administer basic treatment with an injection of RY_SW01 cell solution
Other Names:
|
Experimental: Phase II-high does group
Receive the best basic treatment and two million cells per kilogram of body weight
|
Basic treatment for SSc
Other Names:
Administer basic treatment with an injection of RY_SW01 cell solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of Adverse Events
Time Frame: 24 weeks
|
24 weeks
|
Change of mRSS
Time Frame: 24 weeks
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in mRSS from baseline
Time Frame: 12 weeks
|
12 weeks
|
|
Change in lung function (FVC predicted percentage) from baselineRY_SW01 cell injection.
Time Frame: 24 weeks
|
24 weeks
|
|
Proportion of subjects with treatment failure.
Time Frame: 24 weeks
|
24 weeks
|
|
Proportion of subjects showing improvement in mRSScell injection (Improvement defined as a decrease in mRSS from baseline by ≥25%).
Time Frame: 24 weeks
|
24 weeks
|
|
Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) from baseline to 24 weeks after RY_SW01 cell injection.
Time Frame: 24 weeks
|
24 weeks
|
|
Biological markerTGF-β, VEGF, TNF-a, and Th17 cell subset proportions from baseline to 12 and 24 weeks after RY_SW01 cell injection.
Time Frame: 12weeks 24weeks
|
TNFR1, anti-Scl-70 antibodies, IL-6, TGF-β,TNF-a,Th17
|
12weeks 24weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jing Wang, Jiangsu Renocell Biotech Company
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RYSW202301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
AmgenEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicKorea, Republic of, France, United States, Spain, Mexico, Japan, Argentina, Greece, Israel
-
AmgenRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicNetherlands, Spain, Germany, United States, Japan, France, Italy, Korea, Republic of, Portugal, Israel, Greece, Argentina, Austria, Mexico, Poland, Switzerland, United Kingdom, Romania, Chile
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Kyverna TherapeuticsNot yet recruitingSystemic Sclerosis | Systemic Sclerosis - Diffuse Cutaneous | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on Basic treatment
-
Fuzhou General HospitalRecruitingInfections | COVID-19 | Morality | Death, AssistedChina
-
JemincareShanghai 6th People's HospitalUnknownEfficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to GlomerulonephritisGlomerulonephritis | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3B
-
Xiyuan Hospital of China Academy of Chinese Medical...Recruiting
-
Chinese PLA General HospitalBeijing Jishuitan Hospital; Beijing Aerospace General HospitalUnknownOsteoporosis | Osteopenia, OsteoporosisChina
-
Jieming QUCompleted
-
Wanbangde Pharmaceutical Group Co., LTDSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNot yet recruitingPostoperative Cognitive Dysfunction in Patients With Aneurysmal Subarachnoid HemorrhageChina
-
Harvard UniversityWeiss Family Program Fund for Research in Development Economics; Harvard Lab...Completed
-
Shanghai Mental Health CenterCompleted
-
Jiangsu Famous Medical Technology Co., Ltd.Completed
-
The Third Affiliated hospital of Zhejiang Chinese...RecruitingStroke | DysphagiaChina